Data on BAY 59-7939 at the XXth Congress of the International Society on Thrombosis & Haemostasis (ISTH)

August 6 - 12, 2005 in Sydney, Australia


August 8, 2005:
IR Conference Call - ISTH Review 2005

The audio recording of this event is no longer available.

Background Information
Thromboembolic disorders: A major cause of morbidity and mortalityDownload (PDF, 248 KB) collect
Current anticoagulant therapiesDownload (PDF, 241 KB) collect
Coagulation PathwayDownload (PDF, 81 KB) collect
GlossaryDownload (PDF, 103 KB) collect

ISTH 2005 Abstracts on BAY 59-7939

An Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – For Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: A Dose-ranging Study

Prevention Of Venous Thromboembolism With An Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – In Elective Hip Replacement: A Dose-Ranging Study

Aspirin Has No Effect on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 – an Oral, Direct Factor Xa Inhibitor

Interaction Of BAY 59-7939 – A Novel, Oral, Direct Factor Xa Inhibitor – With Antiplatelet Agents: Monitoring And Therapeutic Applications

Effect Of BAY 59-7939 – A Novel, Oral, Direct Factor Xa Inhibitor – on Clot-Bound Factor Xa Activity In Vitro

Effect of Enoxaparin on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 – an Oral, Direct, Factor Xa Inhibitor

The Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – Inhibits Thrombin Generation In Vitro After Tissue Factor Pathway Activation

Antithrombotic Mechanism of Action of BAY 59-7939 – a Novel, Oral, Direct Factor Xa Inhibitor

Comparison of the Anticoagulant Properties of BAY 59-7939 – an Oral, Direct Factor Xa Inhibitor – with Fondaparinux and Enoxaparin

Last updated: January 13, 2014 Copyright © Bayer AG